Brostallicin
Brostallicin
Brostallicin (pronunciation: bro-sta-lli-cin) is a novel anticancer agent that belongs to the class of DNA minor groove binders. It is a synthetic molecule derived from the natural product distamycin.
Etymology
The term "Brostallicin" is a combination of the prefix "Brosta-", which is derived from the name of the company that first synthesized it, and "-llicin", a common suffix used in the naming of antibiotic and chemotherapeutic agents.
Mechanism of Action
Brostallicin binds to the minor groove of DNA, causing a distortion in the DNA structure. This distortion interferes with the normal functioning of the DNA, leading to cell death. Unlike other minor groove binders, Brostallicin's activity is enhanced in the presence of glutathione, a molecule that is often found in high concentrations in cancer cells.
Clinical Trials
Brostallicin has undergone Phase I and II clinical trials for the treatment of various types of cancer, including sarcoma, ovarian cancer, and colorectal cancer. The results of these trials have shown that Brostallicin has a favorable safety profile and shows promise as a potential treatment for these types of cancer.
Related Terms
- Distamycin: A natural product from which Brostallicin is derived.
- Minor groove binder: A class of molecules that bind to the minor groove of DNA.
- Glutathione: A molecule that enhances the activity of Brostallicin.
- Clinical trial: A type of research study that tests how well new medical approaches work in people.
External links
- Medical encyclopedia article on Brostallicin
- Wikipedia's article - Brostallicin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski